Abstract:Background Cardiovascular disease (CVD) is a major cause of death in China. Despite government efforts, the majority of hypertensive and diabetic patients in China do not receive proper treatment. Reducing CVD events requires long-term care that is proactive, patient-centred, community-based, and sustainable. We have designed a package of interventions for patients at high risk of CVD to be implemented by family doctors based in township hospitals (providers of primary care) in rural Zhejiang, China. This trial aims to determine whether the systematic CVD risk reduction package results in reduced CVD events among patients at risk of CVD compared with usual care, and whether the package is cost-effective and suitable for routine implementation and scale-up. Methods/Design This is a prospective, open-label, cluster randomized controlled trial (RCT) with blinded data analysis. The trial will randomize 67 township hospitals with 31,708 participants in three counties in Zhejiang Province. Participants will be identified from existing health records and will comprise adults aged 50 to 74 years, with a calculated 10-year CVD risk of 20% or higher, or diabetes. In the intervention arm, participants will receive a package of interventions including: 1) healthy lifestyle counseling (smoking cessation, and salt, oil, and alcohol reduction); 2) prescription of a combination of drugs (antihypertensives, aspirin, and statin); and 3) adherence support for drug compliance and healthy lifestyle change. In the control arm, participants will receive usual care for hypertension and diabetes management at individual clinicians’ discretion. The primary outcome is the incidence of severe CVD events over 24 months of follow-up. All CVD events will be defined according to the World Health Organization (WHO) monitoring of trends and determinants in cardiovascular disease (MONICA) definitions, diagnosed at the county hospital or higher level, and reported by the Zhejiang surveillance system. Secondary outcomes include: mean systolic and diastolic blood pressure, blood glucose, serum total cholesterol (TC), and adherence to appointments, and drugs and lifestyle changes. Discussion This trial focuses on risk reduction of CVD rather than specific diseases. It is not designed to compare therapeutic and healthy lifestyle interventions, but rather their combined effects in primary care settings. Through the trial, we intend to understand the effectiveness of the comprehensive CVD reduction package in routine practice. We also intend to understand the barriers and facilitators to implementing the package, and thus to advise on policy and practice change. Trial registration Current Controlled Trials: ISRCTN58988083

Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort

Forecasting And Analyzing The Disease Burden Of Aged Population In China, Based On The 2010 Global Burden Of Disease Study

Cardiovascular Disease Risk Prediction Models in Chinese Population- A Systematic Review and Meta-Analysis

Abstract 4137594: Intrinsic Capacity Trajectories and Cardiovascular Disease among Chinese Older Adults: A Population-Based Longitudinal Study

Cardiovascular Disease Risk Reduction in Rural China: a Clustered Randomized Controlled Trial in Zhejiang

Evaluation of a systematic cardiovascular disease risk reduction strategy in primary healthcare: an exploratory study from Zhejiang, China.

Trends and disparities in China's cardiovascular disease burden from 1990 to 2019

[Prediction on the cardio-cerebrovascular death and probability of premature death caused by common risk factors in China in 2030]

PCN198 THE BURDEN OF ESOPHAGEAL CANCER IN CHINA FROM 2013 TO 2030: A DYNAMIC COHORT MODELING STUDY

Article The Burden of Esophageal Cancer in China From 2013 to 2030 A Dynamic Cohort Modeling Study

The Burden of Chronic Hepatitis C in China from 2004 to 2050: an Individual‐Based Modeling Study

Global burden of cardiovascular diseases: projections from 2025 to 2050

Changing Profiles of Cardiovascular Disease and Risk Factors in China: a Secondary Analysis for the Global Burden of Disease Study 2019.

[Prediction on the burden of disease of chronic obstructive pulmonary disease and simulation of the effectiveness of controlling risk factors in China by 2030].

Trends and patterns in cardiovascular disease mortality in China from 1987 to 2020: a serial cross-sectional analysis (Preprint)

The incidence, mortality and disease burden of cardiovascular diseases in China: a comparative study with the United States and Japan based on the GBD 2019 time trend analysis

The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions

Modelling the Potential Impact of Population-Wide and Targeted High-Risk Blood Pressure-Lowering Strategies on Cardiovascular Disease in China

Development of a Model to Predict 10-Year Risk of Ischemic and Hemorrhagic Stroke and Ischemic Heart Disease Using the China Kadoorie Biobank

Modeling the Health and Economic Burden of Chronic Obstructive Pulmonary Disease in China from 2020 to 2039: A Simulation Study.